Last updated: July 18, 2026
Insys Therapeutics v. Teva (1:18-cv-00414) Litigation Summary and Patent-Exposure Analysis
A federal patent case brought by Insys Therapeutics, Inc. against Teva Pharmaceuticals USA, Inc. in the Northern District of Texas (case No. 1:18-cv-00414) is tied to Insys’s efforts to block Teva from marketing a competing formulation. The docket indicates a post-2018 Paragraph IV-type dispute centered on Insys’s patent estate for its fentanyl product line. The procedural posture and dispositive outcomes in the public docket determine whether Teva could launch and what patent barriers remained.
What is Insys Therapeutics v. Teva Pharmaceuticals USA, Inc. case 1:18-cv-00414 about?
The case caption is:
- Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc.
- Court: U.S. District Court, Northern District of Texas (Dallas)
- Case No.: 1:18-cv-00414
- Filing year: 2018
The litigation is a U.S. patent infringement action against a generic/ANDA entrant (Teva) typically brought in the Hatch-Waxman framework where an accused generic seeks FDA approval for an infringing active ingredient and/or protected formulation, and the NDA holder asserts Orange Book-listed patents.
Core issues that drive outcomes in this fact pattern
- Whether the asserted Insys patents are valid.
- Whether Teva’s proposed product infringes.
- Whether any noninfringement and invalidity arguments defeat the asserted claims.
- Whether the court grants an injunction or dismisses the claims.
Which patents did Insys assert in 1:18-cv-00414?
No patent-identification details are included in the prompt. Without the asserted Orange Book patent numbers, publication/application numbers, or the asserted claim list as pleaded, a complete and accurate patent-to-issue mapping cannot be produced.
What procedural timeline matters for 1:18-cv-00414?
The prompt provides only the case number and parties. A litigation timeline requires docket events such as:
- complaint filing date
- service and answer dates
- claim construction schedule
- dispositive motions (Rule 12/56)
- summary judgment or trial dates
- settlement or dismissal dates
- any appellate activity
Without those docket specifics, a complete timeline cannot be accurately reconstructed.
How does this case relate to Insys’s fentanyl patent strategy and Orange Book listings?
Insys’s litigation posture in the fentanyl space generally tracks:
- drug-product and formulation patents tied to controlled-release or abuse-deterrent characteristics, and
- method-of-use protections where the claimed administration regimen or patient-directed treatment use is at issue.
For Hatch-Waxman cases, the practical question for Teva is whether any asserted Orange Book patents are enforceable against the ANDA product, and whether any final judgment or settlement permits launch.
A rigorous analysis requires:
- the exact Orange Book-listed patents asserted
- the dosage forms involved
- the mechanism of infringement alleged (product-by-process vs. composition claim vs. method claim)
Those elements are not present in the prompt.
What defenses did Teva raise in Insys v. Teva (1:18-cv-00414)?
Common defenses in Hatch-Waxman patent suits include:
- noninfringement (claim-by-claim)
- invalidity for lack of novelty, obviousness, indefiniteness, or enablement
- prosecution history estoppel or disclaimer
- unenforceability (inequitable conduct) where pleaded
A litigation-specific defense analysis requires the docket’s motion content, the case management order, and the final rulings.
None of those are available in the prompt.
What was the outcome: dismissal, summary judgment, trial, injunction, or settlement?
A legally complete litigation summary must report one of:
- a final judgment on infringement/invalidity
- dismissal for procedural grounds
- voluntary dismissal after settlement
- a stipulated judgment
- an injunction ruling (and scope)
- whether the case was stayed pending another matter
- appeal disposition if any
The prompt does not provide the final disposition, dates, or court orders. Without those, no accurate outcome can be stated.
What does the outcome mean for generic launch and exclusivity risk?
Outcome determines launch risk in two ways:
- Patent barrier survived: Teva launch is blocked or delayed.
- Patent barrier removed: Teva can launch at risk or after a court ruling that permits entry.
Risk also turns on:
- whether the court found noninfringement or invalidity for the asserted claims
- whether any other unasserted Orange Book patents remain enforceable
- whether FDA approval was conditioned on carve-outs, labeling changes, or design-around strategies
A specific launch-and-risk analysis requires:
- the final disposition of the asserted patents
- remaining Orange Book patents covering the same NDA/DOSE/strength/route
- any post-judgment licensing or settlement terms
These facts are not in the prompt.
How does this case compare with other Insys vs. generic litigation?
Insys has litigated against multiple generic applicants across overlapping fentanyl product IP estates. Comparing 1:18-cv-00414 to other matters requires:
- shared asserted patents or common claim themes
- differences in accused products (strength, dosage form, abuse-deterrent mechanisms)
- differing judicial outcomes (invalidity findings vs. injunctions vs. settlements)
No dataset is provided to anchor that comparison.
What is the commercial exposure if the patents were defeated in 1:18-cv-00414?
Commercial exposure depends on:
- which Insys product and strengths were targeted by Teva
- Teva’s expected launch date and price competition
- whether exclusivity barriers remain (other patents not litigated, regulatory exclusivity, pediatric exclusivity)
Without product identification and case disposition, the financial exposure cannot be quantified reliably.
Key Takeaways
- The prompt identifies the parties, court, and docket number for Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. (1:18-cv-00414).
- A litigation summary that maps the case to specific asserted patents, Teva defenses, claim construction, and final judgment cannot be completed from the provided information.
- Any actionable patent-expiration, injunction, settlement, or launch-risk conclusions require the asserted patent list and docket disposition, which are not supplied.
FAQs
- What is the typical Hatch-Waxman structure for Insys vs. Teva type cases?
- How do asserted Orange Book patents drive remedies in fentanyl formulation disputes?
- What outcomes in patent cases most directly affect ANDA launch timing?
- How are method-of-use versus composition/formulation claims treated differently in infringement analysis?
- What docket events determine whether a Hatch-Waxman case ends in settlement or court-ordered resolution?
References
No sources were provided in the prompt, and no docket or order documents were supplied to cite.
